Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
01/10/202116h20Business WireTeva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
30/09/202114h00Business WireTeva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCNNYSE:TEVATeva Pharmaceutical Industries Ltd
30/09/202113h30Business WireTeva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPDNYSE:TEVATeva Pharmaceutical Industries Ltd
28/09/202119h39Dow Jones NewsTeva Pharma Shares Up 6% After Louisiana Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
28/09/202118h40Business WireTeva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/202114h00Business WireLate-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and RimegepantNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202123h11Dow Jones NewsTeva, MedinCell Say FDA Accepts NDA for Schizophrenia TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202122h15Business WireTeva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
31/08/202122h15Business WireTeva et MedinCell annoncent l’acceptation par la FDA du dossier de demande d’approbation du traitement TV46000/mdc-IRM pour les patients atteints de schizophrénieNYSE:TEVATeva Pharmaceutical Industries Ltd
30/08/202114h00Business WireShowcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...NYSE:TEVATeva Pharmaceutical Industries Ltd
27/08/202112h11Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/08/202114h00Business WireTeva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive DyskinesiaNYSE:TEVATeva Pharmaceutical Industries Ltd
19/08/202122h04Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/08/202122h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202122h11Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202113h30Business WireTeva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent AnalysisNYSE:TEVATeva Pharmaceutical Industries Ltd
28/07/202113h00Business WireTeva Reports Second Quarter 2021 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/07/202114h00Business WireTeva Announces Changes to Executive Management TeamNYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/202118h14Business WireTeva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021NYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/202111h09TipRanksTeva, Bioeq Partner to Sell Lucentis BiosimilarNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202119h39Business WireTeva und Bioeq geben Vertriebspartnerschaft für Biosimilar bekanntNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202117h46Business WireTeva et Bioeq annoncent un partenariat commercial dans le domaine des biosimilairesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202114h00Business WireTeva and Bioeq Announce Commercial Partnership for BiosimilarNYSE:TEVATeva Pharmaceutical Industries Ltd
23/06/202114h12Business WireTeva Announces Ministry of Health, Labour & Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Tre...NYSE:TEVATeva Pharmaceutical Industries Ltd
23/06/202108h58Business WireNouvelles données relatives à l'innocuité du traitement par COPAXONE® (acétate de glatiramère) chez les mères allaitan...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202123h18Business WireTeva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to T...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202116h36Business WireNeue Sicherheitsdaten zur Behandlung von stillenden Müttern mit COPAXONE® (Glatirameracetat), die mit schubförmig verlaufe...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202110h17Business WireTeva présente de nouvelles données lors du 7e congrès de l’Académie européenne de neurologie, suggérant que des facte...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202108h30Business WireNew Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple S...NYSE:TEVATeva Pharmaceutical Industries Ltd
22/06/202107h24Business WireTeva präsentiert neue Daten auf dem 7. Kongress der European Academy of Neurology, die sozioökonomische Faktoren mit einer ...NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

Delayed Upgrade Clock